Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Oct 15;8(10):17271-80.
eCollection 2015.

Diagnostic value of bone-specific alkaline phosphatase in lung carcinoma patients with bone metastases: a meta-analysis

Qing-Tao Zhao  1 , Zhao-Xu Yang  2 , Lei Yang  3 , Dong Xing  2 , Jing-Chao Wei  2 , Wen-Yi Li  2
Affiliations

Diagnostic value of bone-specific alkaline phosphatase in lung carcinoma patients with bone metastases: a meta-analysis

Qing-Tao Zhao et al. Int J Clin Exp Med. .

Abstract

Aim and Backgrounds: The accurate diagnosis of lung carcinoma patients with bone metastases is crucial for therapy and the prevention of complications. We performed a systematic review and meta-analysis to evaluate the diagnostic value of serum bone-specific alkaline phosphatase (BALP) in lung carcinoma patients with bone metastases.

Methods: Such databases as PubMed, Embase, Cochrane Library, Web of Science, Ovid, BioMed Central, Biosis previews and four Chinese databases (Chinese Biomedical Literature Database-disc (CBM), Chinese National Knowledge Infrastructure (CNKI), Technology of Chongqing (VIP) and Wan Fang DATA) were retrieved on computer, and the relevant journals were also manually searched to collect the trials on BALP in diagnosis of lung carcinoma patients with bone metastases. The meta-analysis was conducted by using Meta-Disc 1.4 software.

Results: A total of 8 studies were included, and there were 848 lung carcinoma patients diagnosed by gold standard, patients were divided into two groups: 419 cases with bone metastases and 429 cases without bone metastases. The meta-analysis showed that, the pooled sensitivity (SEN), specificity (SPE), positive likelihood ratio (PLR), negative likelihood ratio (NLR) and diagnostic odds ratio (DOR) was 0.48 [95% CI (0.43 to 0.53)], 0.86 [95% CI (0.82 to 0.89)], 3.14 [95% CI (2.47 to 3.99)], 0.62 [95% CI (0.56 to 0.68)], 6.66 [95% CI (4.62 to 9.60)] respectively. And the AUC of SROC was 0.78, (Q*=0.72).

Conclusion: BALP has greater diagnostic value in detecting lung carcinoma patients with bone metastases. However, further large scale studies are required to confirm the predictive value.

Keywords: BALP; Lung carcinoma; bone metastases; meta-analysis.

PubMed Disclaimer

Figures

Figure 1
Figure 1
The study selection and inclusion process.
Figure 2
Figure 2
Presentation of QUADAS-2 results.
Figure 3
Figure 3
Summary receiver operating characteristic (SROC) curve for BALP in the diagnosis of Lung carcinoma patients with bone metastases in the 8 included studies.
Figure 4
Figure 4
Forest plot for the diagnostic odds ratio (DOR) of BALP to diagnose Lung carcinoma patients with bone metastases. DOR (diagnostic odds ratio)=6.66 (95% CI, 4.62-9.60).
Figure 5
Figure 5
Forest plot for the sensitivity of BALP to diagnose Lung carcinoma patients with bone metastases. Sensitivity=0.48; (95% CI, 0.43-0.53).
Figure 6
Figure 6
Forest plot for the specificity of BALP to diagnose Lung carcinoma patients with bone metastases. Specificity=0.86 (95% CI, 0.82-0.89).
Figure 7
Figure 7
Forest plot for the positive likelihood ratio (PLR) of BALP to diagnose Lung carcinoma patients with bone metastases. PLR (positive likelihood ratio)=3.14 (95% CI, 2.47-3.99).
Figure 8
Figure 8
Forest plot for the negative likelihood ratio (NLR) of BALP to diagnose Lung carcinoma patients with bone metastases. NLR (negative likelihood ratio)=0.62 (95% CI, 0.56-0.68).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64:9–29. - PubMed
    1. Reck M, Heigener DF, Mok T, Soria JC, Rabe KF. Management of non-small-cell lung cancer: recent developments. Lancet. 2013;382:709–719. - PubMed
    1. Toloza EM, Harpole L, McCrory DC. Noninvasive staging of non-small cell lung cancer: a review of the current evidence. Chest. 2003;123:137S–146S. - PubMed
    1. Tsuya A, Kurata T, Tamura K, Fukuoka M. Skeletal metastases in non-small cell lung cancer: a retrospective study. Lung Cancer. 2007;57:229–232. - PubMed
    1. Rosell R, Bivona TG, Karachaliou N. Genetics and biomarkers in personalisation of lung cancer treatment. Lancet. 2013;382:720–731. - PubMed

LinkOut - more resources